Introduction
Rheumatoid arthritis (RA) is a chronic and inflammatory autoimmune disease that affects elderly individuals worldwide. Severe cases of RA can lead to long-term disability due to significant damage to ligaments and bones. Currently, there is no permanent solution for RA, but there are medications available to manage symptoms. Diagnosing RA can be challenging, especially in the first year of its development. However, the use of next-generation sequencing (NGS) technology can improve the effectiveness of sequencing specific parts of the genome to detect the presence of RA in an individual. This study focuses on the advancements in biomedical research for rheumatoid arthritis, particularly in relation to NGS technology. The research also explores the potential of using ribonucleic acid sequencing to analyze specific fragments associated with RA. NGS has accelerated the diagnostic process for rheumatic diseases, thanks to its advanced genetic analysis capabilities not found in other treatment approaches.
Rheumatoid arthritis and associated complications
Rheumatoid arthritis (RA) is a chronic condition that currently has no known cure. However, the progression of the disease can be slowed down or halted by using disease-modifying medications. Early diagnosis is crucial in order to prevent further damage, as the existing harm to the patient’s body cannot be reversed. Medical experts have identified four key stages of Rheumatoid arthritis (Figure 1) as recommended guidelines.
Insights of next generation sequencing technology
Next-generation sequencing (NGS) technology is a high-throughput method that allows the sequencing of entire genomes and specific DNA or RNA sequences. It has been applied in various fields such as genomics, proteomics, epigenomics, and transcriptomics to study gene expression and genetic diversity. In the case of rheumatoid arthritis (RA), NGS technology plays a crucial role in analyzing genetic alterations and identifying disease-related complications. It enables the sequencing of nucleotide sequences, including DNA methylation, DNA sequencing, and chromatin accessibility, to aid in diagnosis and treatment. NGS provides valuable insights into the genetic complexities and variations associated with immune and autoimmune diseases. It facilitates the study of allelic variations and gene expression through targeted sequencing and RNA-seq analysis. NGS, along with other omics technologies like transcriptomics, epigenomics, and genomics, offers a comprehensive understanding of gene expression, epigenetic changes, and genetic variation on a genome-wide scale.
Transcriptomics
Transcriptomics involves high-throughput techniques for identifying RNA and studying gene expression. In rheumatoid diseases, RNA sequencing is used to analyze gene-wide gene expression patterns. However, the clinical utility of this approach in informing treatment decisions is still being explored. Transcriptome analysis across various tissues and cells in the human body is more complex than sequencing an individual’s genome, as cells have unique transcription profiles that can dynamically change in response to stimuli. Researchers focus on specific cell subsets or perform meta-analyses to capture significant transcriptomic patterns. Next-generation sequencing (NGS) provides scalability and molecular information by considering the expression of all genes and non-coding RNAs, unlike microarray assays. Bulk gene expression evaluation is relatively easier for mixed cell populations, but it may be less efficient in capturing gene expression signatures related to clinical differences and treatment responses. Single-cell expression analysis using NGS allows for profiling individual cells, enabling the study of specific cell subtypes and rare cell types. It provides high-dimensional data for categorization and discovery.
Targeting certain RNA species
Targeting specific RNA species can be achieved by modifying the RNA sequencing protocol to capture desired subtypes such as mRNA, nuclear RNA, nascent transcripts, and ribosome-associated RNA. Paired-end sequencing allows the detection of alternatively spliced isoforms and specific gene targets like non-coding RNA and antigen receptor genes. Epigenomics focuses on studying epigenetic modifications that occur at different levels, including histone protein modifications, DNA chemical alterations, and chromatin accessibility. These epigenetic patterns are dynamic during inflammatory processes, and understanding changes in epigenetics is crucial for rheumatic diseases. Chromatin landscape and histone modification analysis are being used to gain insights into the role of epigenetics in disease states and inflammation, although further research is needed for disease-causing genes in rheumatoid arthritis (RA). DNA methylation analysis using NGS enables genome-wide assessment of DNA methylation patterns. Whole-genome bisulfite sequencing (WGBS) is a commonly used NGS protocol for identifying methylated regions across the genome. NGS has revolutionized genome sequencing by facilitating the discovery of pathogenic variations, rare inherited diseases, and somatic mosaicism.
Role of Next Generation Sequencing (NGS) in Rheumatoid Arthritis
Next-generation sequencing (NGS) technology has revolutionized the field of rheumatoid arthritis (RA) by providing high-throughput and in-depth analysis of genetic, epigenetic, and transcriptomic factors.
NGS techniques enable the identification of disease-causing genes, personalized treatment approaches, and a better understanding of the interplay between genetics and the environment in RA. NGS accelerates diagnostic testing, improves disease management, and may lead to the discovery of new therapeutic targets. It has transformed the field by overcoming previous limitations and facilitating precision medicine in RA. Next-generation sequencing (NGS) technology has significant implications for understanding and analyzing rheumatoid arthritis (RA). It covers various aspects such as genomics, transcriptomics, metagenomics, and epigenomics.
NGS enables whole-genome and exome sequencing, facilitating the identification of genetic complexities and allelic variations in RA. It helps in understanding cellular pathways involved in RA development and provides insights into novel pathogenic conditions. NGS plays a crucial role in identifying targeted genes causing RA through allelic variation analysis. It highlights the correlation between genetic and environmental factors in RA pathogenesis. NGS technology is essential for sequencing coding and non-coding regions of the genome associated with RA-related complications. It aids in the analysis of genetic variants and pathogenesis in RA.
The interaction between chondrocytes and fibroblasts, as well as cartilage destruction, can be studied using NGS. RNA sequencing through NGS provides valuable insights into the genetic diversity and pathogenesis of RA. Non-coding RNAs, such as miRNAs, and their dysregulation in RA can be analyzed using NGS. NGS technology also helps in studying bone homeostasis and identifying genetic changes associated with RA. High-throughput profiling of genome sequences in RA patients enables the identification of functional annotations and miRNA-mRNA interactions. The application of NGS in RA research provides a comprehensive understanding of the disease, including bone erosion and loss in peri-articular areas.
Expression profiling for RA through next generation sequencing technology
Rheumatoid arthritis (RA) is an autoimmune disease caused by immune system dysfunction. The molecular mechanism underlying RA involves synovial fibroblasts (RASF) and can be studied through transcriptome- wide sequencing using NGS technology. NGS enables the integration of mRNA and miRNA analysis in RASF development. Small RNA sequencing and the identification of upregulated and downregulated mRNA and miRNA sequences play a crucial role in developing diagnostic tools for RA. NGS allows for comprehensive analysis of the regulatory network and miRNA target interactions in RA. Understanding the regulatory interactions between miRNAs and small RNA sequences is important for studying the development of RA.
Advantages of next generation sequencing (NGS) technologies in the case of RA
NGS technologies have significant advantages in studying the pathogenicity and genetic aspects of rheumatoid arthritis (RA). They enable the analysis of subclonal variations and genetic diversity within the RA population. NGS helps identify mutations and provides insights for appropriate therapeutic interventions in RA. It also allows for consensus sequence-based correction of gene sequence errors related to RA. NGS technologies are effective in sequencing nucleic acids such as mRNA, DNA, and small RNA sequences, providing a large-scale understanding of genetic variability in RA.
Conclusion
Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain and swelling. It cannot be cured, but various treatments can help manage the symptoms. Next-generation sequencing (NGS) technology has shown promise in understanding the genetic aspects of RA and developing targeted therapies. NGS facilitates the identification of gene sequences associated with RA and enables RNA and exome sequencing. Although there are limitations in current literature regarding complications in new variant sequencing, it has accelerated the diagnosis of rheumatic diseases and holds potential for improving treatment approaches.
References:
1. Jacob L, Rockel T, Kostev K. Depression risk in patients with Rheumatoid Arthritis in the United Kingdom. Rheumatol Ther. 2017;4:195–200.EGYPTIAN JOURNAL OF BASIC AND APPLIED SCIENCES151.
2. Devaraj NK. The difficult rheumatology diagnosis. Ethiop J Health Sci. 2018 Jan;28 (1):101–102.
3. Bagchi S, Genardi S, Wang CR. Linking CD1-Restricted T cells with autoimmunity and dyslipidemia: lipid levels Matter. Front Immunol. 2018;9.
4. Burmester GR, Pope JE. Novel treatment stra-tegies in rheumatoid arthritis. Lancet. 2017;389:2338–2348.
5. Cheung P, Khatri P, Utz PJ, et al. Single-cell technologies — studying rheumatic diseases one cell at a time. Nat Rev Rheumatol. 2019;15:340–354.
6. Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Gene. 2018;19:269–285.
7. Ware JS, Roberts AM, Cook SA. Next generation sequencing for clinical diagnostics and personalized medicine: implications for the next generation cardiologist. Heart. 2012;98:276–281.
8. Aletaha D, Smolen JS. Diagnosis and management of Rheumatoid Arthritis. JAMA. 2018;320:1360.
9. Kwiatkowska B, Kłak A, Malinska M, et al. Factors of depression among patients with rheumatoid arthritis. Reumatologia/ Rheumatology. 2018;56:219–227.
10. Salmeron JL, Rahimi SA, Navali AM, et al. Medical diagnosis of Rheumatoid Arthritis using data driven PSO–FCM with scarce data-sets. Neurocomputing. 2017;232:104–112.
11. Pennell NA, Mutebi A, Zhou Z-Y, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;(3):1–9.
12. Murphy D, Mattey D, Hutchinson D. Anti- citrullinated protein antibody positive rheumatoid arthritis is primarily determined by rheumatoid factor titre and the shared epitope rather than smoking per se. PLOS ONE. 2017;12:e0180655.
13. Lin J, Shi X, Fang S, et al. Comparative tran-scriptome analysis combining SMRT and NGS sequencing provides novel insights into sex differentiation and development in mud crab (Scylla paramamosain). Aquaculture. 2019;513.
14. Alpizar-Rodriguez D, Lesker TR, Gronow A, et al. Prevotella copri in individuals at risk for rheuma-toid arthritis. Ann Rheu Dis. 2019;78:590–593.
15. Mülkoglu C, Alpoguz Yılmaz Z, Nacır B, et al. Pseudothrombophlebitis syndrome in a rheumatoid arthritis patient with swollen calf and persistent itching: a case report. BMC Musculoskelet Disord. 2018;19:345.
16. Pfeiffer F, Gröber C, Blank M, et al. Systematic evaluation of error rates and causes in short samples in next-generation sequencing. Sci Rep. 2018;8:10950.
17. Bodkhe R, Balakrishnan B, Taneja V. The role of microbiome in rheumatoid arthritis treatment. Ther Adv Musculoske Dis. 2019;11:1759720X1984463.
18. Gudelj I, Salo PP, Trbojevic-Akmacic I, et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim Biophys Acta (BBA) – Mol Basis Dis. 2018;1864:2034–2039.
19. Slatko BE, Gardner AF. Ausubel FM overview of next-generation sequencing technologies. Curr Protoc Mol Biol. 2018;122.
20. Srivastava S, Patel S, Singh D, et al. Rationalized insights on causes of rheumatoid arthritis in the elderly and women: special emphasis on treatment strategies. Crit Rev TM er Drug Carrier Syst. 2017;34:97–147.
